Avita Medical Expands Commercial Reach for ReCell® in Wound Care Market with the Appointment of Distributors in France and the UK

/in ,

Northridge, CA, USA and Cambridge, United Kingdom, 24 November 2015. Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced that it has entered into agreements with specialist wound-care distributors in France and the UK. In France, Medical Z® is a leader in […]

Read more

Avita Medical Announces AUD$ 10M Equity Financing

/in ,

Australia, 20 October 2015 — ASX link here. Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, announced today the closing of a AUD$ 10,018,644 common stock placement to sophisticated and institutional investors through the issue of 107,727,358 shares at a price of AUD $0. […]

Read more

Avita Medical Announces Positive Interim Clinical Study Results On Restoration of Pigment in Burn Scars at Clinical Cosmetic & Reconstructive Expo

/in ,

Avita Medical announcement link here. · POSITIVE RESULTS FROM INTERIM UPDATE ON 20-PATIENT, RANDOMIZED, CONTROLLED STUDY OF RESTORATION OF PIGMENT IN HYPOPIGMENTED BURN SCARS · CONTINUED POSITIVE DATA FROM REPIGMENTATION TRIALS TO FORM BASIS FOR PIII PIVOTAL IDE SUBMISSION WITH US FDA NORTHRIDGE, Calif., and CAMBRIDGE, United Kingdom, 18 October 2013– Regenerative medicine Company Avita Medical Ltd. (ASX: AVH), (OTCQX:AVMXY) is […]

Read more

Avita Medical Gains CE Mark for ReGenerCell® and ReNovaCell® to Complete Skin Healing Portfolio Certification Applies to ReCell®, ReGenerCell® and ReNovaCell®

/in ,

Northridge, CA and Cambridge, United Kingdom, 7 October 2015 Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a medical device company specializing in the treatment of wounds and skin defects, today announced it has received CE Mark authorization to market in Europe that will allow it to define and target its autologous cell suspension technology for […]

Read more

Avita Medical Announces U.S. FDA Doubles Patient Numbers Permitted for Compassionate Use of ReCell®

/in ,

Northridge, CA and Cambridge, United Kingdom, 5 October 2015 Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced approval from the U.S. Food and Drug Administration (FDA) for the expansion of its Compassionate Use Investigational Device Exemption (IDE) program for ReCell®. The IDE […]

Read more

Avita Medical Awarded US Government Contract valued at up to $53. 9 m USD

/in ,

Link here. 30 September 2015. Highlights: BARDA contract commits initial USD16.9m to support Avita’s FDA approval trial for treatment of thermal burn injuries and procure 5000-plus ReCell® devices. Contract also establishes a strategic, Avita-managed stockpile for ReCell® devices to supply nationally. A further potential to receive USD37M in contract options to support additional clinical trials and […]

Read more